Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,739 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo low dose Clear all
Completed Phase 2 Interventional

A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone

NCT06862791
View directory record Official record
Conditions
Obesity or Overweight
Interventions
AZD9550, AZD6234, Placebo comparator
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
29
States / cities
Dothan, Alabama • Vestavia Hills, Alabama • Cerritos, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 2, 2026, 5:58 PM EDT
Completed Phase 3 Interventional Results available

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

NCT00538850
View directory record Official record
Conditions
Cancer
Interventions
Fentanyl sublingual spray, Placebo
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Chandler, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Sep 2, 2026, 5:58 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Safety and Tolerability of a Recombinant Herpes Zoster Vaccine

NCT05750017
View directory record Official record
Conditions
Herpes Zoster, Vaccine-Preventable Diseases
Interventions
Low Dose Recombinant Herpes Zoster Vaccine (LZ901), High Dose Recombinant Herpes Zoster Vaccine (LZ901), Placebo
Biological · Drug
Lead sponsor
Beijing Luzhu Biotechnology Co., Ltd.
Other
Eligibility
50 Years to 70 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 26, 2023 · Synced Sep 2, 2026, 5:58 PM EDT
Completed Phase 3 Interventional

Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach

NCT00345618
View directory record Official record
Conditions
Embolism, Thrombosis
Interventions
Idrabiotaparinux sodium, Warfarin, Placebo (for idrabiotaparinux sodium), Avidin, Placebo (for warfarin), Enoxaparin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
3,202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 20, 2016 · Synced Sep 2, 2026, 5:58 PM EDT
Terminated Phase 4 Interventional Results available

Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism

NCT04558125
View directory record Official record
Conditions
Pulmonary Embolism, COVID
Interventions
TNKase, Placebo, Enoxaparin
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Sep 2, 2026, 5:58 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

KBP-201 COVID-19 Vaccine Trial in Healthy Volunteers

NCT04473690
View directory record Official record
Conditions
Covid19
Interventions
Low Dose of KBP-COVID-19, High Dose of KBP-COVID-19, Placebo
Biological
Lead sponsor
KBio Inc
Industry
Eligibility
18 Years to 85 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
6
States / cities
West Palm Beach, Florida • Meridian, Idaho • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated May 17, 2025 · Synced Sep 2, 2026, 5:58 PM EDT
Recruiting Phase 3 Interventional

Massive Transfusion in Children-2: A Trial Examining Life Threatening Hemorrhage in Children

NCT06070350
View directory record Official record
Conditions
Hemorrhagic Shock, Trauma Injury
Interventions
Low Titer Group O Whole Blood (LTOWB), Placebo, Tranexamic Acid (TXA), Component Therapy (CT)
Biological · Drug
Lead sponsor
Philip Spinella
Other
Eligibility
Up to 17 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
23
States / cities
Tucson, Arizona • Little Rock, Arkansas • Sacramento, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 2, 2026, 5:58 PM EDT
Terminated Phase 2 Interventional Results available

Dose Finding Study on BI54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat® Inhaler in Asthmatic Patients Inadequately Controlled on Short-acting-beta-agonist (SABA) Therapy

NCT01397162
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone propionate, Placebo, BI 54903
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
12 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
41
States / cities
Fountain Valley, California • Huntington Beach, California • Long Beach, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2022 · Synced Sep 2, 2026, 5:58 PM EDT
Completed Phase 3 Interventional Results available

A Research Study of an Investigational Drug ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride) in Patients With Moderate to Severe Chronic Low Back Pain

NCT01571362
View directory record Official record
Conditions
Chronic Pain, Low Back Pain, Analgesia
Interventions
ALO-02, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
52
States / cities
Mobile, Alabama • Goodyear, Arizona • Phoenix, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Sep 2, 2026, 5:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Single Ascending Doses of IW-3300 in Healthy Volunteers

NCT05188261
View directory record Official record
Conditions
Healthy Volunteers
Interventions
IW-3300, Placebo
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 7, 2023 · Synced Sep 2, 2026, 5:58 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1™ Adjuvant

NCT02078674
View directory record Official record
Conditions
Influenza (Pandemic)
Interventions
Monovalent Avian Influenza VLP (H7N9), Matrix-M1™ adjuvant, Placebo
Biological
Lead sponsor
Novavax
Industry
Eligibility
18 Years to 64 Years
Enrollment
610 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
5
States / cities
Walnut Creek, California • Miami, Florida • Meridian, Idaho + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Sep 2, 2026, 5:58 PM EDT
Recruiting Phase 2 Interventional

Efficacy of LoDoCo in Improving Exercise Capacity Among Patients With HFpEF and Inflammation

NCT06130059
View directory record Official record
Conditions
Heart Failure, Inflammation
Interventions
Low Dose Colchicine, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 2, 2026, 5:58 PM EDT
Withdrawn Phase 1 Interventional

Safety, Tolerability, and Efficacy of RLS103 in Subjects With Acute Anxiety Within Social Anxiety Disorder (SAD)

NCT05429788
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
Low dose RLS103, High dose RLS103, placebo inhaled dry powder
Drug
Lead sponsor
Receptor Life Sciences
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
3
States / cities
Los Angeles, California • Oceanside, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Sep 2, 2026, 5:58 PM EDT
Completed Phase 2 Interventional Results available

Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney Disease

NCT02697617
View directory record Official record
Conditions
Polycystic Kidney Disease
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Sep 2, 2026, 5:58 PM EDT
Completed Phase 2 Interventional Results available

Fasitibant Intra-articular Injection in Patients With Symptomatic Osteoarthritis of the Knee

NCT02205814
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Fasitibant- low dose, Fasitibant- intermediate dose, Fasitibant- high dose, Placebo comparator
Drug
Lead sponsor
Menarini Group
Industry
Eligibility
40 Years to 80 Years
Enrollment
436 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
9
States / cities
Tucson, Arizona • Englewood, Colorado • DeLand, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2015 · Synced Sep 2, 2026, 5:58 PM EDT
Completed Phase 3 Interventional Results available

A Randomized, Double-Blind, Dose Response-Control, Crossover Study to Evaluate the Safety and Efficacy of Two Doses of EUR-1008 (APT-1008) in Chronic Pancreatitis (CP) Participants With Exocrine Pancreatic Insufficiency (EPI)

NCT00788593
View directory record Official record
Conditions
Chronic Pancreatitis, Exocrine Pancreatic Insufficiency
Interventions
Placebo, EUR-1008 (APT-1008) High Dose, EUR-1008 (APT-1008) Low Dose
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
9
States / cities
Little Rock, Arkansas • Los Angeles, California • Gainesville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2014 · Synced Sep 2, 2026, 5:58 PM EDT
Terminated Phase 2 Interventional

A Phase 2 Randomized Double-Blind, Parallel, Adaptive-Design, Clinical Trial to Evaluate the Safety and Efficacy of NRCT-101SR With NRCT-202XR Compared to NRCT-202XR Alone in Subjects With Attention-Deficit/Hyperactivity Disorder

NCT06673368
View directory record Official record
Conditions
ADHD
Interventions
NRCT-101SR, NRCT-202XR
Drug
Lead sponsor
Neurocentria, Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
5
States / cities
Maitland, Florida • Decatur, Georgia • Savannah, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Sep 2, 2026, 5:58 PM EDT
Active, not recruiting Phase 2 Interventional

Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)

NCT06956235
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Tulisokibart, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
19
States / cities
Birmingham, Alabama • Phoenix, Arizona • Rogers, Arkansas + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 2, 2026, 5:58 PM EDT
Completed Phase 2 Interventional

A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II Study

NCT00567710
View directory record Official record
Conditions
Schizophrenia
Interventions
BL - 1020, Placebo, Risperidone
Drug
Lead sponsor
BioLineRx, Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Irving, Texas
Source: ClinicalTrials.gov public record
Updated Jun 28, 2010 · Synced Sep 2, 2026, 5:58 PM EDT
Completed Phase 2 Interventional Results available

CAP-Ketamine for Antidepressant Resistant PTSD

NCT02655692
View directory record Official record
Conditions
PTSD, Posttraumatic Stress Disorder
Interventions
Ketamine, Placebo/Saline
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 70 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
West Haven, Connecticut • Minneapolis, Minnesota • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 1, 2022 · Synced Sep 2, 2026, 5:58 PM EDT
Completed Phase 3 Interventional Results available

Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Telangiectasia Patients

NCT02770807
View directory record Official record
Conditions
Nervous System Disease, Genetic Syndrome
Interventions
EryDex Low dose DSP, EryDex High dose DSP, Pooled Placebo
Drug
Lead sponsor
Quince Therapeutics S.p.A.
Industry
Eligibility
6 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Sep 2, 2026, 5:58 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)

NCT06537414
View directory record Official record
Conditions
Chronic Hepatitis B Virus Infection, Hepatitis B
Interventions
Daplusiran/Tomligisiran Dose Level 1, Daplusiran/Tomligisiran Dose Level 2, Bepirovirsen, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
5
States / cities
San Francisco, California • San Jose, California • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 2, 2026, 5:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3015014 in Otherwise Healthy Participants With High Low-density Lipoprotein (LDL) Cholesterol

NCT01618916
View directory record Official record
Conditions
Healthy Volunteers
Interventions
LY3015014, Placebo
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
Honolulu, Hawaii • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 14, 2019 · Synced Sep 2, 2026, 5:58 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Antagonism of Opioid-Induced Respiratory Depression by CX1739 With Preservation of Opioid Analgesia

NCT02735629
View directory record Official record
Conditions
Opiate Induced Respiratory Depression
Interventions
CX1739 - 300 mg, CX1739 - 600 mg, CX1739 - 900 mg, Placebo
Drug
Lead sponsor
RespireRx
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 27, 2016 · Synced Sep 2, 2026, 5:58 PM EDT